CP-104 Adherence to disease modifying antirheumatic drugs in patients with rheumatoid arthritis

BackgroundA lack of adherence to disease modifying antirheumatic drugs (DMARDs) can increase inflammatory activity (IA) in patients with rheumatoid arthritis (RA).PurposeTo estimate adherence to subcutaneous biological (DMARD-b) and conventional (DMARD-c) DMARDs in RA patients. To evaluate IA as a function of DMARD adherence.Material and methodsCross sectional study in pharmaceutical care outpatients with RA receiving DMARD-b at a 550 bed hospital in April 2015.Study variables: age, sex, DMARDs, adherence and IA.Adherence was evaluated by two indirect methods: (1) patient self-administered questionnaire (CQR5-Compliance Questionnaire Rheumatology); and (2) electronic dispensation records, calculating the ‘medication possession rate’ (MPR), defined as the number of days a medication was dispensed divided by the number of days of the treatment period during the previous 12 months.‘Adherent’ patients were defined by MPR ≥80% and CQR5 classification of ‘high adherence’.DAS28 was used to evaluate IA as in remission (DAS28 ≤2.6), low (DAS28 ≤3.2) or moderate (DAS28 >3.2). 0.05) and moderate in 38.9% vs. 38.4% (p > 0.05), respectively.Conclu